Embecta (EMBC) Expected to Announce Quarterly Earnings on Thursday

Embecta (NASDAQ:EMBC) is expected to be announcing its Q1 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $0.67 per share and revenue of $258.0660 million for the quarter. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:00 AM ET.

Embecta (NASDAQ:EMBC) last announced its earnings results on Tuesday, November 25th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.04. The company had revenue of $263.30 million for the quarter, compared to the consensus estimate of $265.66 million. Embecta had a net margin of 8.83% and a negative return on equity of 24.62%. The company’s revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.45 EPS. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Stock Down 0.3%

Shares of Embecta stock opened at $10.91 on Wednesday. Embecta has a 12 month low of $9.20 and a 12 month high of $18.58. The stock has a market cap of $645.98 million, a PE ratio of 6.69 and a beta of 1.11. The business has a fifty day simple moving average of $11.87 and a 200-day simple moving average of $12.98.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Friday, December 5th were given a dividend of $0.15 per share. The ex-dividend date was Friday, December 5th. This represents a $0.60 dividend on an annualized basis and a yield of 5.5%. Embecta’s dividend payout ratio (DPR) is presently 36.81%.

Institutional Trading of Embecta

Several large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its holdings in shares of Embecta by 11.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 789,509 shares of the company’s stock valued at $11,140,000 after purchasing an additional 81,218 shares in the last quarter. Ameriprise Financial Inc. increased its position in Embecta by 439.1% during the second quarter. Ameriprise Financial Inc. now owns 709,849 shares of the company’s stock worth $6,878,000 after buying an additional 578,174 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Embecta by 39.5% in the third quarter. JPMorgan Chase & Co. now owns 434,822 shares of the company’s stock worth $6,135,000 after buying an additional 123,113 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of Embecta by 103.6% during the 2nd quarter. Squarepoint Ops LLC now owns 403,412 shares of the company’s stock worth $3,909,000 after acquiring an additional 205,311 shares in the last quarter. Finally, Qube Research & Technologies Ltd increased its holdings in shares of Embecta by 83.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 362,935 shares of the company’s stock valued at $3,517,000 after acquiring an additional 164,570 shares during the last quarter. 93.83% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on EMBC shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. Wall Street Zen raised shares of Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 27th. Zacks Research lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. Finally, BTIG Research reissued a “buy” rating on shares of Embecta in a research note on Tuesday, November 25th. One research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $18.50.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.